LEADER 02217nam  2200577   450 
001 9910779873003321
005 20230803021102.0
010   $a1-78084-270-8
010   $a1-78084-271-6
035   $a(CKB)2550000001101935
035   $a(EBL)1179645
035   $a(OCoLC)854971660
035   $a(SSID)ssj0001599928
035   $a(PQKBManifestationID)16306258
035   $a(PQKBTitleCode)TC0001599928
035   $a(PQKBWorkID)14892839
035   $a(PQKB)11287715
035   $a(MiAaPQ)EBC1179645
035   $a(Au-PeEL)EBL1179645
035   $a(EXLCZ)992550000001101935
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEmerging therapeutic options for hepatitis C /$feditors, Masao Omata, Tatsuo Kanda
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (117 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-272-4 
327   $aTitle page; Copyright page; Contents; Foreword. Hepatitis C virus infection: from discovery to eradication; 1. Interferons in clinical trials; 2. Protease inhibitors; 3. NS5A inhibitor: daclatasvir; 4. Toll-like receptor agonists for nonresponders to hepatitis C virus treatment: hope versus promise?; 5. Treatment options in HIV-HCV-coinfected patients; 6. Treatment options for dual hepatitis C/hepatitis B virus coinfection; 7. Hepatitis C virus treatment in patients with metabolic syndrome; 8. Future directions in hepatitis C therapy; Index
330   $aEmerging Therapeutic Options for Hepatitis C
606   $aHepatitis C$xTreatment
606   $aHepatitis C$xChemotherapy
606   $aAntiviral agents
615  0$aHepatitis C$xTreatment.
615  0$aHepatitis C$xChemotherapy.
615  0$aAntiviral agents.
676   $a616.362306
702   $aOmata$b Masao
702   $aKanda$b Tatsuo
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910779873003321
996   $aEmerging therapeutic options for hepatitis C$93763873
997   $aUNINA